Physician profile
James B Fox
NPI 1740487354
$7,011.83
in general payments reported to CMS, 2019-2025
31 companies · $1,422 in 2025
The $1,422 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $771 · 2020: $805 · 2021: $1,039 · 2022: $832 · 2023: $948 · 2024: $1,195 · 2025: $1,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,564.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,061.47 | 2019-2025 | Rexulti, Nuedexta |
| Sunovion Pharmaceuticals INC. | $617.64 | 2019-2022 | |
| Abbvie INC. | $609.31 | 2021-2025 | |
| Lundbeck LLC | $598.25 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $446.31 | 2019-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Supernus Pharmaceuticals, INC. | $411.99 | 2022-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $389.47 | 2019-2025 | Trintellix |
| Alkermes, INC. | $331.63 | 2022-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $326.42 | 2022-2025 | Caplyta |
| Livanova USA, INC. | $291.34 | 2021-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Corium, LLC | $286.88 | 2023-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $284.15 | 2023-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $248.62 | 2023-2025 | Auvelity, Sunosi |
| Teva Pharmaceuticals USA, INC. | $154.78 | 2020-2025 | Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $145.54 | 2022-2025 | Fanapt, Hetlioz |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $106.42 | 2024-2025 | Cobenfy |
| Eisai INC. | $97.02 | 2020-2022 | |
| Allergan, INC. | $83.02 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $76.39 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $74.96 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $58.71 | 2025 | Quviviq |
| Collegium Pharmaceutical, INC. | $55.15 | 2025 | Jornay Pm |
| Bausch Health US, LLC | $45.54 | 2020 | |
| Noven Therapeutics, LLC | $41.20 | 2025 | Xelstrym |
| Tris Pharma INC | $37.77 | 2023 | Dyanavel Xr |
| Almatica Pharma LLC | $31.19 | 2025 | Loreev Xr |
| Shire North American Group INC | $28.39 | 2019 | |
| Dexcom, INC. | $23.75 | 2025 | Dexcom G6 Transmitter |
| Indivior INC. | $19.32 | 2024 | Sublocade |
| Neos Therapeutics, LP | $15.62 | 2025 | Exxua |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.58 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.